AU5420494A - Method of reducing multidrug resistance in cells and tissues - Google Patents

Method of reducing multidrug resistance in cells and tissues

Info

Publication number
AU5420494A
AU5420494A AU54204/94A AU5420494A AU5420494A AU 5420494 A AU5420494 A AU 5420494A AU 54204/94 A AU54204/94 A AU 54204/94A AU 5420494 A AU5420494 A AU 5420494A AU 5420494 A AU5420494 A AU 5420494A
Authority
AU
Australia
Prior art keywords
tissues
cells
multidrug resistance
reducing multidrug
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54204/94A
Inventor
Yves Claude Nicolau
Pierre-Francois Tosi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU5420494A publication Critical patent/AU5420494A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU54204/94A 1992-11-02 1993-11-02 Method of reducing multidrug resistance in cells and tissues Abandoned AU5420494A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97041692A 1992-11-02 1992-11-02
US970416 1992-11-02
PCT/EP1993/003073 WO1994010198A1 (en) 1992-11-02 1993-11-02 Method of reducing multidrug resistance in cells and tissues

Publications (1)

Publication Number Publication Date
AU5420494A true AU5420494A (en) 1994-05-24

Family

ID=25516918

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54204/94A Abandoned AU5420494A (en) 1992-11-02 1993-11-02 Method of reducing multidrug resistance in cells and tissues

Country Status (3)

Country Link
EP (1) EP0669941A1 (en)
AU (1) AU5420494A (en)
WO (1) WO1994010198A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046254A2 (en) * 1996-06-05 1997-12-11 Eugene Mechetner Reagents and methods for inhibiting cytokine release by blood cells
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
FR2857875A1 (en) * 2003-07-25 2005-01-28 Univ Reims Champagne Ardenne Immunogenic composition containing fatty acid-modified peptides from protein P-170, useful e.g. for reversing multidrug resistance of cancer cells
EP2603233A1 (en) 2010-08-12 2013-06-19 AC Immune S.A. Vaccine engineering
CN103189050B (en) * 2010-10-26 2017-09-29 Ac免疫有限公司 The construct based on liposome comprising the peptide modified by hydrophobic part
WO2016172193A1 (en) * 2015-04-20 2016-10-27 New Mexico Tech Research Foundation Antibiotic sensitivity-restoring and photosensitive agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837306A (en) * 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
WO1987005943A1 (en) * 1986-03-28 1987-10-08 Board Of Trustees Of University Of Illinois Compositions and methods for clones containing dna sequences associated with multidrug resistance in human cells
NZ230423A (en) * 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
WO1990001948A1 (en) * 1988-08-25 1990-03-08 The Liposome Company, Inc. Influenza vaccine and novel adjuvants
ES2138588T3 (en) * 1990-06-29 2000-01-16 Chiron Corp COMPOSITIONS OF VACCINES CONTAINING LIPOSOMES.
AU1239892A (en) * 1991-01-04 1992-08-17 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A method for constructing antigens
US5773280A (en) * 1992-03-20 1998-06-30 The Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
IT1257893B (en) * 1992-06-17 1996-02-16 Ist Superiore Sanita MONOCLONAL ANTIBODIES THAT RECOGNIZE AN EPITOPE OF HUMAN P-GLYCOPROTEIN.

Also Published As

Publication number Publication date
EP0669941A1 (en) 1995-09-06
WO1994010198A1 (en) 1994-05-11

Similar Documents

Publication Publication Date Title
AU3470493A (en) Photovoltaic cell and method
AU1840695A (en) Improvement in solar cell modules and method of making same
AU1915095A (en) Improvement in solar cell modules and method of making same
AU675983B2 (en) Rectangular cell and its fabrication method
AU7369794A (en) Shaped lead structure and method
AU1644295A (en) Cell culture substrates and methods of use
AU6635196A (en) Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
AU4105796A (en) Signage articles and methods of making same
AU4655296A (en) Compositions and methods for treating tumor cells
AU5693698A (en) Improved electrodes and method of use
AU7968894A (en) Pacemaker and method of fabrication
AU3497395A (en) Irradiation catheter and method of use
AU3201093A (en) Dental composition and method
AU5603494A (en) Isotonic energy composition and method to use same
AU7319994A (en) Nucleotide preparation and uses thereof in wound healing
AU4758093A (en) Method of increasing hair shine and repairing alkaline-damaged hair
PL319531A1 (en) Basic voltaic cell and method of making same
AU6043396A (en) Composition and methods for creating syngeneic recombinant v irus-producing cells
AU4774093A (en) Free radical scavengers useful for reducing autofluorescence in fixed cells
AU5420494A (en) Method of reducing multidrug resistance in cells and tissues
AU6905894A (en) Trichohyalin and transglutaminase-3 and methods of using same
AU1052795A (en) Compositions and methods for transduction of cells
AU3973595A (en) Hair mother cell activator and method of activating hair mother cell
AU4631496A (en) Improvements in and relating to swarf removal
AU3805593A (en) Phosphate selective composition and electrode